Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28587975 | 0.79 | POLB (0.44) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL4122601 | 0.75 | CA12 (0.46) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL22048950 | 0.75 | OPRM1 (0.41) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL21994844 | 0.73 | OPRM1 (0.40) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL22163905 | 0.72 | OPRM1 (0.48) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL12919599 | 0.70 | POLB (0.55) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL348946 | 0.68 | OPRM1 (0.57) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23094453 | 0.68 | OPRM1 (0.47) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL10696393 | 0.68 | OPRM1 (0.50) | POLBOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL22397059 | 0.67 | POLB (0.51) | POLBOPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | POLB 2869/4885OPRM1 203/4885OPRD1 325/4885 |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | POLB 2869/4885OPRM1 203/4885OPRD1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.